30-Second Takeaway
- Perioperative probiotics/synbiotics may shorten GI recovery and reduce postoperative infections after colorectal surgery.
- Treatment delays (>6 weeks) associate with worse overall survival in early age-onset colorectal cancer.
Week ending June 6, 2026
Selected recent evidence relevant to colorectal surgical practice
Probiotics may reduce chemo-related diarrhea and speed GI recovery after colorectal surgery
This systematic review of trials and meta-analyses through September 2025 found probiotic supplementation reduced clinically relevant chemotherapy-associated diarrhea, most consistently for severe diarrhea and select subgroups. Perioperative probiotics or synbiotics in colorectal surgery were associated with faster return of GI function, fewer postoperative infections, and shorter length of stay in pooled randomized evidence. No probiotic-strain invasive infections were reported in the included controlled studies, but rare serious events exist in broader literature. Heterogeneity in formulations, outcome definitions, and few large trials limit certainty; strain-specific, adequately powered RCTs are needed.
Delays >6 weeks to definitive therapy predict worse survival in early age-onset CRC
Population-based analysis of 112,672 Texas cancer registry patients found 11% had early age-onset CRC (age <50 years). Treatment delays >6 weeks from diagnosis to definitive therapy were associated with worse overall survival (adjusted HR ~1.29), independent of other factors. Higher Social Vulnerability Index and language barriers were also independently associated with delayed treatment and worse outcomes. Median overall survival for EOCRC exceeded follow-up, but delay remained prognostically significant on multivariable analysis.
ARS criteria: margin-negative resection is key in locoregionally recurrent rectal cancer
Multidisciplinary guideline and systematic review (116 trials) conclude the ability to achieve a margin-negative resection determines survival and local control in LRRC. Preoperative systemic therapy, radiation, or both can downsize tumors and improve chances of margin-negative resection. Treatment choice should be individualized by prior therapy and recurrence site, within a multidisciplinary framework. The panel did not recommend major practice changes but reinforced combined-modality planning to maximize resectability.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.